Company intelligence / Profile preview
ACEA Therapeutics
San Diego, California, United Statesaceatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
ACEA Therapeutics has completed a pivotal Phase III clinical trial of Olgotrelvir for COVID-19 with over 1200 patients. Their lead oncology compound Abivertinib has completed Phase II studies for EGFR T790M+ NSCLC in China with positive results. Multiple other compounds are in various stages of clinical development.
- Therapeutic areas
- OncologyImmunologyInfectious DiseasesHematology
- Modalities
- Small moleculesLarge moleculesCell therapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Sorrento Therapeutics
Beyond the preview
Go deeper on ACEA Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACEA Therapeutics.